This page is an automatically generated summary of information from the Federal Court, Federal Court of Appeal, Health Canada and other websites. This information should NOT be relied upon as it is automatically generated and has not been confirmed for accuracy.
Automatically generated on December 15, 2023.
Return to the list of Patented Medicine Litigation page.
Adalimumab
HUMIRA – AbbVie Corporation (NOC Search)
Patents:
- 1329542:
- 1329760:
- 2241319:
- 2243459: SANDOZ, MYLAN
- 2282931:
- 2385745: , SANDOZ, MYLAN, JAMP
- 2494756: , SANDOZ, MYLAN, JAMP
- 2504868: JAMP, SANDOZ, MYLAN,
- 2745743:
- 2801917: , JAMP
- 2815689: JAMP
- 2847142: , SANDOZ, MYLAN, JAMP
- 2872089:
- 2882905:
- 2882907:
- 2882931:
- 2882934:
- 2898009: JAMP,
- 2904458: JAMP,
- 2947487:
- 6090382: SANDOZ, MYLAN
Unknown/Other
- Impeachment – T-1355-17 – T-2009-19
- PM(NOC) – T-1048-20 (2020 FC 1013) – T-598-17 (2017 FC 675, 2017 FC 676) – T-599-17 – T-600-17 – T-601-17 – T-602-17 – T-603-17 – T-604-17 – T-605-17 – T-870-20
- Appeal – A-203-22
- Correction of Patent Office Records – T-1842-21
JAMP
- PM(NOC) – A-348-23 – T-10-22 (2022 FC 1209, 2022 FC 1538) – T-130-22 – T-557-21 (2023 FC 1520) – T-559-21 – T-560-21 – T-561-21
- Impeachment – T-572-21 – T-573-21 – T-577-21 – T-581-21
SANDOZ, MYLAN
- Other – T-649-23
Return to the Patented Medicine Litigation page.